Home
XOMA

XOMA

XOMA Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

as 04-26-2024 4:00pm EST

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Founded:	N/A	Country:	United States
Employees:	N/A	City:	EMERYVILLE
Market Cap:	282.1M	IPO Year:	N/A
Target Price:	$74.00	AVG Volume (30 days):	18.6K
Analyst Decision:	Strong Buy	Number of Analysts:	1
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-4.04	EPS Growth:	N/A
52 Week Low/High:	$13.48 - $27.00	Next Earning Date:	05-07-2024
Revenue:	$4,758,000	Revenue Growth:	-21.06%
Revenue Growth (this year):	202.27%	Revenue Growth (next year):	46.45%

Share on Social Networks:

Latest XOMA Corporation News

XOMA Breaking Stock News: Dive into XOMA Ticker-Specific Updates for Smart Investing

$XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)$